MUC1 and non-small cell lung carcinoma: TG4010 and first-line chemotherapy significantly improved overall survival (OS) (HR 0.67, p = 0.018) and progression-free survival (PFS) (hazard ratio [HR] 0.66, p = 0.010) in the predefined TrPAL-low subgroup of patients with MUC1-positive advanced NSCLC.